EUVIMEDEUVIMED entdecken
Crossref

Current State of Allogeneic Hematopoietic Cell Transplantation for Still Disease: A Collaborative Perspective From Attendees of the Systemic Juvenile Idiopathic Arthritis Foundation NextGen Conference

Sharat Chandra iD, Rebecca A Marsh, Juliana M F Silva, Holly Wobma iD, Susan Prockop, Mary Slatter, Lauren A Henderson iD, Grant S Schulert iD, Alexei Grom, Rashmi Sinha, James A Connelly

Arthritis Care & Research · 03.11.2026

DOI: 10.1002/acr.80191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 03.11.2026. Verfasst von Sharat Chandra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio. Die Arbeit nennt 36 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Systemic juvenile idiopathic arthritis and adult‐onset Still disease represent a spectrum of Still disease characterized by dysregulated innate immunity, severe systemic inflammation, and risk of life‐threatening complications including macrophage activation syndrome (MAS) and associated lung disease (LD). Although interleukin‐1 (IL‐1) and IL‐6 pathway inhibitors have improved outcomes, a subset of patients develop severe, refractory disease. This article summarizes the current evidence and multidisciplinary expert perspectives on the role of allogeneic hematopoietic cell transplantation (HCT) in refractory Still disease.

Methods

This Special Article is a conference summary based on presentations and multidisciplinary discussion at the 2024 Systemic Juvenile Idiopathic Arthritis Foundation NextGen Conference, which convened an international, multidisciplinary group of rheumatologists, transplant physicians, immunologists, pulmonologists, and patient advocates.

Results

Recurrent MAS, progressive LD, persistent systemic inflammation despite IL‐1/IL‐6/JAK inhibition, and glucocorticoid dependence were identified as clinical features that may warrant consideration of allogeneic HCT in Still disease. Available data, mainly from small pediatric cohorts, suggest that allogeneic HCT can achieve clinical remission and improve pulmonary outcomes in select patients. However, transplant‐related mortality remains substantial, particularly in patients with LD, and inflammatory disease may recur after HCT. HCT data in adults remain limited.

Conclusion

Allogeneic HCT may be considered for select patients with severe, refractory Still disease, particularly those with recurrent MAS and/or progressive LD. Early multidisciplinary evaluation, shared decision‐making, and careful patient selection are essential. Prospective multicenter studies and closer collaboration between pediatric and adult providers are needed to refine patient selection and improve outcomes.

Autor:innen und Institutionen

  • Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Department of Bone Marrow Transplant, Great Ormond Street Hospital for Children, London, UK.
  • Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Dana Farber Cancer Institute/Boston Children's Hospital Center for Cancer and Blood Disorders, Boston, Massachusetts.
  • Department of Paediatric Immunology and Haematopoietic Stem Cell Transplantation, Great North Children's Hospital, Newcastle Upon Tyne, UK.
  • Systemic Juvenile Idiopathic Arthritis Foundation, Cincinnati, Ohio.

ORCID-Profile: Sharat Chandra, Holly Wobma, Lauren A Henderson, Grant S Schulert

Zitieren

APA

Chandra, S., Marsh, R. A., Silva, J. M. F., Wobma, H., Prockop, S., Slatter, M., Henderson, L. A., Schulert, G. S., Grom, A., Sinha, R., & Connelly, J. A. (2026). Current State of Allogeneic Hematopoietic Cell Transplantation for Still Disease: A Collaborative Perspective From Attendees of the Systemic Juvenile Idiopathic Arthritis Foundation NextGen Conference. Arthritis Care & Research. https://doi.org/10.1002/acr.80191

Vancouver

Chandra S, Marsh RA, Silva JMF, Wobma H, Prockop S, Slatter M, et al. Current State of Allogeneic Hematopoietic Cell Transplantation for Still Disease: A Collaborative Perspective From Attendees of the Systemic Juvenile Idiopathic Arthritis Foundation NextGen Conference. Arthritis Care & Research. 2026. doi:10.1002/acr.80191

BibTeX
@article{Chandra2026,
  author = {Chandra, Sharat and Marsh, Rebecca A and Silva, Juliana M F and Wobma, Holly and Prockop, Susan and Slatter, Mary and Henderson, Lauren A and Schulert, Grant S and Grom, Alexei and Sinha, Rashmi and Connelly, James A},
  title = {Current State of Allogeneic Hematopoietic Cell Transplantation for Still Disease: A Collaborative Perspective From Attendees of the Systemic Juvenile Idiopathic Arthritis Foundation NextGen Conference},
  journal = {Arthritis Care & Research},
  year = {2026},
  doi = {10.1002/acr.80191}
}
Kostenlos starten →